Mirae Asset Global Investments
AARD

Mirae Asset Global Investments’s Aardvark Therapeutics AARD Stock Holding History

Mirae Asset Global Investments’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.62K Sell
976
-160
-14% -$748 ﹤0.01% 1618
2026
Q1 		$4.28K Buy
1,136
+78
+7% +$809 ﹤0.01% 1533
2025
Q4 		$13.9K Buy
+1,058
New +$13.2K ﹤0.01% 1582

Other funds holding AARD

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
AHL
Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HHCP
Hilton Head Capital Partners Hilton Head Island, South Carolina $198M AUM
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return

Mirae Asset Global Investments's AARD Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Aardvark Therapeutics (AARD) stake by 14% in Q2 2026, selling an estimated $748 and leaving 976 shares worth $5.62K. The position accounts for ﹤0.01% of the portfolio, ranked #1618.

Mirae Asset Global Investments first reported a position in AARD in Q4 2025 and has held it in 3 quarters since. The position peaked at $13.9K in Q4 2025. 13 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • Mirae Asset Global Investments held 976 shares of Aardvark Therapeutics worth $5.62K as of Q2 2026.
  • Mirae Asset Global Investments sold 160 Aardvark Therapeutics shares in Q2 2026, an estimated $748.
  • Aardvark Therapeutics made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1618 holding.
  • Mirae Asset Global Investments first reported a position in Aardvark Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Mirae Asset Global Investments's Aardvark Therapeutics position peaked at $13.9K in Q4 2025.
  • 13 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.